Lenvatinib
Educational summary, not a formulary. Dosing is quoted from the Makindo chapters and topics site. The other sections are draft summaries not yet checked line by line against the BNF or SPC. Check dose, indication, interactions and monitoring in the BNF entry for Lenvatinib and local guidelines before prescribing.
Tyrosine kinase inhibitor
Mechanism
Multi-kinase inhibitor.
Uses
Thyroid, renal cell, hepatocellular and endometrial cancers.
Dosing
No dose is given in the chapters. See the BNF.
Side effects
Hypertension, proteinuria, fatigue, diarrhoea, haemorrhage.
Interactions
Few.
Contraindications and cautions
Uncontrolled hypertension
Monitoring
BP, urine protein, TFT
Pregnancy and breastfeeding
Contraindicated
Renal and hepatic impairment
Reduce dose in severe renal or hepatic impairment
Overdose and reversal
Supportive
Special advice
Control BP before starting.
More from the textbook: uses, cautions and other points
- Lenvatinib or sorafenib as alternatives.
Gastroenterology: Cirrhosis and Transplantation - Lenvatinib / sorafenib | Alternative systemic treatments for advanced HCC.
Gastroenterology: Cirrhosis and Transplantation - Bevacizumab , and TKIs such as sunitinib, pazopanib, cabozantinib, lenvatinib.
Oncology: Principles - Immunotherapy combinations - nivolumab with ipilimumab, or pembrolizumab or nivolumab with a TKI (axitinib, lenvatinib, cabozantinib).
Oncology: Urology and Genital cancers
Where it is discussed in the book
- Gastroenterology: Cirrhosis and Transplantation (2 mentions)
- Oncology: Principles (1 mention)
- Oncology: Urology and Genital cancers (1 mention)